Novo Nordisk teams with OpenAI; new Wegovy dose okayed

Novo Nordisk said on April 14 it is bringing OpenAI into drug research and factory work as it rolls out a new, higher-dose Wegovy option in Britain. (novonordisk.com) (gov.uk) The company said the OpenAI partnership will span work from drug discovery to commercial operations, with “strict data governance and human oversight” built into the arrangement. Novo Nordisk said the goal is to help employees move faster across development and delivery. (biospace.com) In the United Kingdom, the Medicines and Healthcare products Regulatory Agency said on April 14 it approved a new single-dose 7.2 milligram semaglutide pen for adults with obesity and a body mass index of 30 kilograms per square meter or higher. The agency said the pen gives patients one injection to reach the maximum weekly dose. (gov.uk) Semaglutide is the active ingredient in Wegovy, a medicine that mimics a gut hormone involved in appetite and blood sugar control. In January 2026, the same British regulator cleared a maximum 7.2 milligram weekly dose, but that version required three separate 2.4 milligram injections on the same day. (gov.uk 1) (gov.uk 2) Novo Nordisk has spent 2026 adding new versions and claims around Wegovy as competition in obesity drugs has intensified. On March 19, the company said the United States approved Wegovy HD, its 7.2 milligram semaglutide product, and cited 20.7% mean weight loss in the STEP UP trial. (novonordisk.com) (sciencehub.novonordisk.com) That trial enrolled 1,407 adults with obesity and no diabetes, according to Novo Nordisk materials. A plain-language summary on the company’s science site said people who took semaglutide 7.2 milligrams as intended lost 20.7% of body weight, compared with 17.5% on 2.4 milligrams and 2.4% on placebo. (sciencehub.novonordisk.com) The company has also been widening how Wegovy is used and shipped in Europe. On April 9, Novo Nordisk said Wegovy became the first glucagon-like peptide-1, or GLP-1, weight-loss treatment approved in the European Union for 48-hour controlled-temperature delivery. (novonordisk.com) British regulators said the new 7.2 milligram single-dose pen applies to adults with obesity, not to overweight patients below that body mass index threshold who use Wegovy for weight management, and not to patients using Wegovy to lower the risk of serious heart problems. The agency said it will keep the drug’s safety and effectiveness under close review. (gov.uk) Taken together, the April 14 moves show Novo Nordisk pushing on two fronts at once: software to shorten the path from lab to market, and a simpler high-dose pen for a drug it already sells. Both bets center on the same pressure point in 2026 — getting obesity treatments to patients faster and with fewer hurdles. (biospace.com) (gov.uk)